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Function of Human 345 Nicotinic Acetylcholine
Receptors Is Reduced by the 5(D398N) Variant*
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Andrew A. George‡, Linda M. Lucero‡, M. Imad Damaj§, Ronald J. Lukas‡, Xiangning Chen¶, and Paul Whiteaker‡1
From the ‡Division of Neurobiology, BarrowNeurological Institute, Phoenix, Arizona 85013 and the §Department of
Pharmacology/Toxicology and ¶Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia 23298
Background:The naturally occurring5(D398N) variant alters smoking behavior, but functional differences have not been
detected between 345 nAChR harboring these variants.
Results: ACh-induced 345 nAChR function is lower when 5(Asn-398) substitutes for 5(Asp-398).
Conclusion: The 5 variant-induced change in 345 nAChR function may underlie some of the phenotypic changes asso-
ciated with this polymorphism.
Significance: 345 nAChR function may be a useful target for smoking cessation pharmacotherapies.
Genome-wide studies have strongly associated a non-synon-
ymous polymorphism (rs16969968) that changes the 398th
amino acid in thenAChR5 subunit fromaspartic acid to aspar-
agine (D398N), with greater risk for increased nicotine con-
sumption. We have used a pentameric concatemer approach to
express defined and consistent populations of 345 nAChR
in Xenopus oocytes. 5(Asn-398; risk) variant incorporation
reduces ACh-evoked function compared with inclusion of the
common5(Asp-398) variantwithout altering agonist or antag-
onist potencies. Unlinked 3, 4, and 5 subunits assemble to
form a uniform nAChR population with pharmacological prop-
erties matching those of concatemeric 34* nAChRs. 5 sub-
unit incorporation reduces 34* nAChR function after coin-
jection with unlinked 3 and 4 subunits but increases that of
345 versus 34-only concatemers. 5 subunit incorpora-
tion into 34* nAChR also alters the relative efficacies of
competitive agonists and changes the potency of the non-com-
petitive antagonist mecamylamine. Additional observations
indicated that in the absence of 5 subunits, free 3 and 4
subunits form at least two further subtypes. The pharmacologi-
cal profiles of these free subunit34-only subtypes are dissim-
ilar both to each other and to those of 345 nAChR. The 5
variant-induced change in 345 nAChR function may
underlie some of the phenotypic changes associated with this
polymorphism.
Nicotinic acetylcholine receptors (nAChR)2 are prototypical
members of the ligand-gated ion channel superfamily of neu-
rotransmitter receptors. nAChR exist as a diverse family of
molecules composed of different pentameric combinations of
homologous subunits derived from at least 17 genes (1-10,
1-4, , , ). The properties of nAChR are determined by
their subunit composition, giving rise tomultiple subtypes with
a range of overlapping pharmacological and biophysical prop-
erties (1). It also has become apparent that different stoichiom-
etries of the same subunits can produce subtypeswith distinctly
different characteristics, a phenomenon observed in both het-
erologous and natural expression systems (1–5).
Recently, genome-wide association studies have indicated
that single-nucleotide polymorphisms (SNPs) within nAChR
subunits can substantially affect nAChR-mediated smoking
behavior in humans. Most prominent among these single-nu-
cleotide polymorphisms have been those located in the
CHRNA5/CHRNA3/CHRNB4 locus, located on chromosome
15q25, which encodes the 5, 3 and 4 subunits of nicotinic
receptors. This locus was first associated with nicotine depend-
ence (6). Subsequent studies confirmed associations of single-
nucleotide polymorphisms at this locus with heavy smoking
(25 cigarettes smoked daily), Fagerström Test for Nicotine
Dependence scores and age dependent severity of nicotine
dependence (7–11). One non-synonymous polymorphism
(rs16969968), which changes the 398th amino acid from aspar-
tic acid to asparagine (D398N) in the 5 subunit, is particularly
strongly associatedwith greater risk for increased nicotine con-
sumption. Interestingly, variants at this locus also are associ-
ated with increased liability for lung cancer (8, 12, 13), and
possibly with decreased risk for alcoholism (7, 14) and cocaine
dependence (15).
These observations raise the question of what the functional
effects of the D398N mutation might be. The 5 subunit can
only assemble into functional nAChR when expressed with at
least two other subunits (1). In the central nervous system,most
5 subunit expression occurs in combination with 4 and 2
subunits (16, 17). Experiments using heterologous expression
systems have demonstrated that 42* nAChR containing 5
subunits harboring the risk (Asn-398) variant have lower func-
tion than those that incorporate 5 subunits with the common
(Asp-398) variant (11, 18). This provides a mechanism through
* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
Grants R21 DA027070–02S1 (to P. W., X. C., M. I. D., and R. J. L.) and
R21 DA026627 (to P. W.). This work was also supported by an endowment
and capitalization funds from the Men’s and Women’s Boards of the Bar-
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sented as a Society for Neuroscience abstract (46).
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which the 5(D398N) mutation could produce phenotypic
effects. Notably, a restricted set of brain regions (most promi-
nently in the habenuolopeduncular pathway) express 5 sub-
units in combination with 3 and 4 subunits (19, 20), as often
occurs in autonomic 34* nAChR (21–23). A recent study
showed that increased expression of34* nAChR in the habe-
nulopeduncular tract of mice increases nicotine aversion, an
effect that can be reduced by the introduction and expression of
additional5(Asn-398) subunits in the same pathway (20). Fur-
thermore, 3, 4, and 5 nAChR subunits are commonly
expressed in bronchial, epithelial, and lung cancer cells, where
nAChR activation by nicotine has been proposed as a mecha-
nism that may increase tumor initiation and/or growth (24).
However, heterologous expression studies done to date have
not identified functional differences induced by 5 variant
incorporation into 34* nAChR (18, 25).
Other observations may help to explain this discrepancy
between in vitro observations and in vivo phenotypes. It has
been shown that 34 nAChR can be expressed in multiple
stoichiometries, with different functional properties (26–28).
Moreover, 5 subunits can “compete” with 4 subunits for
incorporation into assembled nAChR (29), possibly forcing for-
mation of non-functional nAChR subunit assemblies as “dead
end intermediates” (30). Thus, the effect(s) of common5(Asp-
398) versus risk5(Asn-398) variant subunit incorporation into
34* nAChR may be obscured by changes, attendant on any
5 subunit incorporation, in the overall level of 34 nAChR
functional expression and/or the balance of functional stoichi-
ometric isoforms expressed. This complication in experimental
interpretation is compounded when various mixtures of
nAChR subtypes with specific subunit ratios are expressed
from “loose” subunits assembled under host cell, and not inves-
tigator, control.
To overcome these difficulties in interpretation, we em-
ployed a concatemeric nAChR approach (Fig. 1). Here, nAChR
constructs are assembled that encode all five subunits of the
desired 34* nAChR subtypes joined by short peptide linkers.
The advantage of this approach is that complex nAChR sub-
types can be expressed with native nAChR-like properties and
with completely defined subunit ratios and orders of assembly
(5, 31). Using concatemeric 345 nAChR, we demonstrate
that, as is true for 42* nAChR, incorporation of the 5(Asn-
398) variant reduces maximal acetylcholine-induced function
when compared with the 5(Asp-398) variant. The properties
of the defined concatemeric nAChR also were compared with
those of 34* nAChR allowed to assemble freely from loose
individual subunits. These comparisons confirmed that con-
catemeric and freely assembled 345 nAChR have essen-
tially indistinguishable pharmacological properties. Interest-
ingly, these comparisons also suggested that loose 3 and 4
subunits associate quite differently in the presence or absence
of 5 subunits.
EXPERIMENTAL PROCEDURES
Chemicals—All buffer components and pharmacological
reagents (acetylcholine, atropine, cytisine, nicotine, and
mecamylamine) were purchased from Sigma. Fresh stock drug
solutions were made daily and diluted as required.
Constructs for Individual 3, 4, and 5 nAChR Subunits—
Native human subunit protein sequences for 3, 4, and 5
(both Asn-398 and Asp-398 variants) nAChR subtypes were
encoded by nucleotide sequences optimized for expression in
vertebrate expression systems (synthesized by GeneArt AG;
Invitrogen). Optimizations included minimization of high GC
content sequence segments, improved codon usage, reduction
of predicted RNA secondary structure formation, and removal
of sequence repeats and possible alternative start and splice
sites. Sequences were subcloned into the pSGEM oocyte high
expression vector (a kind gift of Prof.Michael Hollmann; Ruhr-
Universitaet, Bochum, Germany).
Concatemeric 34 and 345 Constructs—Fully pentam-
eric nAChR concatemers were constructed from human
nAChR subunits. cDNAs encoding concatemers were created
using the same subunit layout as successfully used to encode
high and low agonist sensitivity 42* nAChR isoforms (5).
Subunits were arranged in the order 4-3-4-3-X, where X
was either 4, 3, 5(Asp-398) or 5(Asn-398); Fig. 1A. Kozac
and signal peptide sequences were removed from all subunit
sequences with the exception of subunits expressed in the first
position of the concatemer. As previously demonstrated, the
initial - subunit protein pairs of the constructs will assemble
to form an orthosteric binding site between the complementary
() face of the initial 4 subunit and the principal () face of
the following 3 subunit (4). The assembled 34* nAChR
concatemers thus contain orthosteric agonist binding pockets
at the4()/()3 interfaces between the first and second and
between the third and fourth subunits (5). As for individual
subunits, native human subunit protein sequences were
encoded by nucleotide sequences optimized for expression in
vertebrate expression systems (synthesized by GeneArt AG).
Optimizations fell in the same categories as those previously
described. Subunits were linked by alanine-glycine-serine
(AGS) repeats designed to provide a complete linker length
(including the C-terminal tail of the preceding subunit) of 40
2 amino acids. At the nucleotide level, linker sequences were
designed to contain unique restriction sites that allow easy
removal and replacement of individual 3, 4, and 5 subunits
(Fig. 1A). Sequences of all subunits together with their associ-
ated partial linkers were confirmed by DNA sequencing
(Geneart AG). Each concatemer was subcloned into the
pSGEMoocyte high expression vector. Correct assembly of the
concatemers into the expression vector was verified by restric-
tion digest (Fig. 1, A and B). Additionally, concatemers were
digestedwith ScaI to further diagnose the stoichiometry of each
construct (* as indicated; Fig. 1B).
RNA Synthesis—Plasmids containing single 3, 4, or 5
(Asn-398 and Asp-398 variants) nAChR subunits or 34 and
345 concatemeric constructs were linearized with NheI (2
h at 37 °C) and treated with proteinase K (30 min at 50 °C).
cRNAs were transcribed using mMessage mMachine T7 kit
(Applied Biosystems/Ambion, Austin, TX). Reactions were
treated with TURBO DNase (1 unit for 15 min at 37 °C), and
cRNAs were purified using Qiagen RNeasy Clean-up kit
(Valencia, CA). cRNApurity was confirmed on a 1% agarose gel
(Fig. 1B), and preparations were stored at80 °C.
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Oocyte Preparation and RNA Injection—Methods of oocyte
isolation and processing for receptor expression have previ-
ously been described (32, 33) but were modified as follows.
Lobes were digested with 0.75 units/ml LiberaseTM (Roche
Applied Science), and oocytes were incubated at 13 °C. The tips
of pulled glass micropipettes were broken to achieve an outer
diameter of 40 m (resistance of 2–6 milliohms), and
pipettes were used to inject 20–60 nl containing 10 ng of
cRNA/oocyte.
Expression of 34 and 345 Constructs in Xenopus
Oocytes—Seven days after injection, Xenopus oocytes express-
ing loose 3 and 4 with or without 5 (Asn-398 and Asp-398
variants) subunits from individual cRNAs at the indicated
ratios or 34 and 345 concatemers were voltage-clamped
at 70 mV with an Axoclamp 900A amplifier (Molecular
Devices, Sunnyvale, CA). Recordings were sampled at 10 kHz
(low-pass Bessel filter, 40 Hz; high pass filter, DC), and the
resulting traceswere saved to disk (MolecularDevices Clampex
v10.2).Data fromoocyteswith leak currents (Ileak)50nAwere
excluded from recordings. Known nAChR agonists and antag-
onists were applied using a 16 channel, gravity-fed, perfusion
system with automated valve control (AutoMate Scientific,
Inc.; Berkeley, CA). All solutions contained atropine sulfate (1.5
M) to ensure that muscarinic responses were not recorded.
FIGURE 1. Linked (concatemeric) subunit design of 345 receptors. A, shown is a schematic illustration of (from top to bottom) 43434,
43433, 43435(Asp-398), and 43435(Asn-398) constructs. Each construct is flanked with AscI and EcoRV restriction sites (5 and 3,
respectively; indicated by gray circles) for subcloning into high expression oocyte vectors. Kozac and the 4 signal peptide (SP) were retained only for the 1st
position. Flanking each subunit position are unique restriction sites (indicated by gray circles) used in concatemer design (for example, AscI and XbaI used in
exchanging nAChR subunits at position 1; XbaI andAgeI siteswere used in exchanging nAChR subunits at position 2; etc.). Concatemers varied in composition
only at position 5, containing either the 4, 3, or two naturally occurring variants of the 5 nAChR subunit (aspartic acid (Asp-398) or asparagine (Asn-398)).
Stop codons (SC) were added at the 3 end of subunit position 5. The number of AGS repeats flanking each subunit is listed below each linker region. B, shown
is stoichiometry of 43434, 43433, 43435(Asp-398), and 43435(Asn-398) constructs. Concatemers form pentameric receptors by
joining the positive interface of the nAChR subunit at position 1 (P1) and the negative interface of position 5 (P5). Restriction digest (below each schematic)
using unique restriction sites (as mentioned above) was used to verify each subunit within its respective position (P1-P5). An additional restriction digest (*)
using ScaI was performed to diagnose correct subunit composition and order.M, molecular mass markers.
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Oocytes-expressing loose subunits and/or concatemeric
345 nAChR were perfused with receptor agonist (e.g.ACh,
cytisine, and nicotine) or antagonist (e.g.mecamylamine) for 5 s
with 60 s washout times between each subsequent application
of drug.
Data Analysis—EC50 or IC50 values and peak current ampli-
tudes (Imax) were determined from individual oocytes. All stim-
ulation protocols began with stimulation by amaximally effica-
cious dose of ACh (1 mM). This ensured that oocytes were
indeed expressing functional nAChR before we did further
recording, and it provided an internal control response for each
oocyte. Relative agonist efficacies were calculated by compari-
son to this internal ACh control response. EC50 and IC50 values
were determined through non-linear least squares curve-fitting
(GraphPad Prism 4.0, GraphPad Software, Inc., La Jolla, CA)
using unconstrained, monophasic logistic equations to fit all
parameters, including Hill slopes. Additional normalization
was used to compare absolute agonist efficacy between the con-
catemeric nAChR constructs. As for the nAChR expressed
from loose subunits, all peak current response data were col-
lected at 7 days post-injection. Function produced by oocytes
expressing (34)25(Asp-398) concatemerswas chosen as the
internal reference point for each batch of injected oocytes, as
5(Asp-398) is the more-common variant. Responses to 1 mM
ACh, which is a maximally effective concentration for all of the
constructs studied here, were measured. The mean function
produced by oocytes injected with (34)25(Asp-398) con-
catemers on each experimental day was used to normalize all of
the data collected on that day. All four concatemeric constructs
were tested in each experiment. In this way, any residual batch-
to-batch oocyte variation could be accounted for.
EC50 and IC50 values are presented as the mean 95% con-
fidence interval (CI). Data were analyzed using Student’s t test
to compare pairs of groups or by one-way or two-way ANOVA
and Tukey’s multiple comparison test to compare the means of
three or more groups (PRISM, GraphPad Software, Inc.).
RESULTS
Introduction of the 5 Subunit Produces 34* Receptors
with Distinct Pharmacological Responses—In an initial experi-
ment to assess if co-injection of 5 subunits altered functional
responses of 34* nAChR, oocytes were injected with equal
amounts of 3 and 4 RNA (1:1 injection ratio) or with equal
amounts of 3, 4, and 5 RNA (1:1:1 injection ratio). The
concentration-response profiles of the resulting nAChR popu-
lations are illustrated in Fig. 2. The introduction of 5 signifi-
cantly decreased ACh potency at the 34* nAChR population
(Fig. 2A; from 59 M (CI, 54–65 M) to 172 M (CI, 158–187
M; p  0.05)) and approximately halved the maximum ACh-
induced nAChR function (data not showndue to normalization
in Fig. 2). In contrast, the introduction of 5 had no effect on
cytisine potency at 34* nAChR (Fig. 2B; mean 34 and
345 EC50 values, 21 M (CI, 18–24.8 M) and 20.5 M (CI,
17.7–24 M), respectively; p 0.05). However, the addition of
5 subunits significantly reduced relative cytisine efficacywhen
compared with the internal, maximally effective, 1 mM ACh
control (Fig. 2B;34 (1:1) 90.0 1.9% and345 (1:1:1)
34.1 0.7%, p 0.05). The 34-only nAChR population also
FIGURE 2. Concentrations response profiles for 345 nAChR expressed as loose subunits.Oocytes injected with RNA for 3, 4, and 5 subunits in a
1:1 or 1:1:1 ratiowere perfusedwith nAChR agonists acetylcholine (105.5 to 102; n 6) (A), cytisine (106.25 to 102.5; n 6) (B), nicotine (106.25 to 102; n
6) (C), or the34 nAChR antagonistmecamylamine (108 to 104; n 6) (D). Data points represent averages (S.E.). Differences in drug potency and efficacy
between groups were analyzed using one-way ANOVA with Tukey’s post hoc comparison (see “Experimental Procedures”).
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differed slightly from the 345 population in sensitivity to
nicotine (21 M (CI, 18–26 M) to 45 M (CI, 40–51 M)
respectively; p  0.001). Similar to the situation with cytisine,
introduction of the5 subunit also reduced the relative efficacy
of nicotine (% of internal ACh control per oocyte 89.8 2.2%
for 34-nAChR compared with 48.7  1.2% for 345-
nAChR; p  0.001). Most strikingly, introduction of the 5
subunit increased the sensitivity of 34* nAChR to the non-
competitive antagonist mecamylamine by more than an order
of magnitude (34-only IC50  5.5 M (CI, 4.4–6.7 M);
345 IC50 0.40 M (CI, 0.38–0.49 M); p 0.0001).
Effects of Common (Asp-398) and Risk (Asn-398) Variant 5
Subunit Integration into Concatenated 34 Receptors—As
noted in the introduction, 5 subunits could potentially affect
nAChR function in a variety ofways. These could include “com-
petition” with 4 subunits for incorporation into assembled
nAChR (29) and/or trapping as dead end intermediates of sub-
units that might otherwise assemble into functional nAChR
(30). Self-assembly of individual nAChR subunits could also
result in mixed populations of 34 and 345 nAChR sub-
types, possibly in proportions that vary between individual
oocytes. To remove these confounds, we designed pentameric
concatemers that enforce precise subunit ratios and assembly
orders. The resulting constructs encoded functional nAChR as
(34)25(Asn-398) and (34)25(Asp-398) forms. We also
produced concatemers as (34)24 and (34)23 isoforms
for comparison to concatemers containing 5 subunits. These
constructs are displayed schematically in Fig. 1A.
No significant differences in agonist sensitivity (EC50) were
observed among concatemers when 4, 3, or 5 nAChR sub-
units were present in the 5th pentameric position (Fig. 3A; p
0.05). In fact, EC50 values for multiple agonists were similar
across each of the concatemeric constructs and to those meas-
ured for345 nAChR assembled from individual subunits at
1:1:1 cRNA ratios (Fig. 3A-C, Table 1; ACh, p 0.05; cytisine,
p 0.05; nicotine, p 0.05).
Cytisine consistently demonstrated partial agonism across
the concatemeric 34* nAChR constructs (Fig. 3B). The
efficacy of cytisine (normalized to responses to 1 mM ACh)
was indistinguishable between (34)25(Asp-398) and
(34)25(Asn-398) concatemers (25.5  0.6 to 27.3  0.5%;
respectively; p  0.05). However, cytisine efficacy was signifi-
cantly reduced at (34)24 tethered pentamers (Fig. 3B;
19.1  0.8%; p  0.001) and still further at (34)23
constructs (Fig. 3B; 6.0  0.3%; p  0.001). Similarly, nicotine
consistently demonstrated partial agonism across the set of
concatemeric 34* nAChR constructs but evoked progres-
sively weaker responses (as a % of 1mMACh control responses)
in oocytes expressing (34)25(Asp-398) (57.4  2.7%) or
(34)25(Asn-398) (53.5  2.5%) assemblies as opposed to
(34)24 (43.3  2.6%) or (34)23 (26.6  1.7%) concate-
mers (Fig. 3C; latter two reductions p  0.001). Overall, the
FIGURE 3.Positional effects and functional sensitivity of concatenated3,4,5(Asp-398) and5(Asn-398) nAChR subunits.Concentration response
curves were generated for linked 34 nAChR containing 4 at position 5 (open circles), 3 at position 5 (open boxes), 5(Asp-398) variant at position 5 (filled
circles), and 5(Asn-398) variant at position 5 (filled boxes). Concentration response curves were generated for known 34 nAChR agonists acetylcholine
(34)2(4); n  16; (34)2(3); n  11; (34)25(Asp-398); n  17; (34)25(Asn-398); n  17) (A), cytisine (34)2(4); n  6; (34)2(3); n  6;
(34)25(Asp-398); n 10; (34)25(Asn-398); n 10) (B), and nicotine (34)2(4); n 6; (34)2(3); n 6; (34)25(Asp-398); n 8; (34)25(Asn-
398); n  8) (C). D, concentration response curves were also obtained using the 34 antagonist, mecamylamine (34)2(4); n  6; (34)2(3); n  6;
(34)25(Asp-398); n 8; (34)25(Asn-398); n 8). Data points represent averages (S.E.). For cytisine, nicotine, andmecamylamine, comparisons were
made by normalizing current responses as % 1 mM ACh (see “Experimental Procedures”). Differences in drug potency and efficacy between groups were
analyzed using one-way ANOVA with Tukey’s post hoc comparison (see “Experimental Procedures”).
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presence of an 5 subunit in the concatemers resulted in
expression of nAChR with increased partial agonist efficacy by
cytisine and nicotine compared with that for actions at non-5
34* concatemeric nAChR.
In contrast, the potency of the non-competitive antago-
nist mecamylamine decreased significantly on the order
(34)24  (34)23  (34)25 (Fig. 3D, Table 1; p 
0.0001). However, no significant differences in IC50 values were
observed between (34)25(D398) and (34)25(N398)
concatemers (p 0.05). Again, the mecamylamine IC50 values
recorded from 345 nAChR were very similar regardless of
whether these nAChR were assembled from individual sub-
units or from concatemeric constructs (see last three lines of
Table 1).
Only Intact nAChR Concatemers Contribute to Recorded
Function—In some cases, the covalent linkers within concate-
meric constructs have been observed to break down. This lib-
erates smaller products that can assemble to form functional
byproducts (4, 34, 35). To determine if this potential confound
was present in our system, the 5(V9S) “gain-of-function”
mutant was coinjected with either a concatemeric construct
(34)24 or with individual 3 and 4 nAChR subunits.
Assembly of the 5(V9S) subunit with either single subunits or
abridged concatemers would result in a substantial gain of
function (34, 36). Co-expression of 5(V9S) with unlinked 3
and 4 subunits produced a significant increase in function
(peak current amplitude elicited by 1 mM ACh; Fig. 4A). This
demonstrates that the5(V9S) subunit can assemblewith non-
linked subunits as predicted. As previously noted, co-injection
of a non-gain-of-function 5 subunit at a 1:1:1 ratio approxi-
mately halves 34* function. This suggests that comparing
nAChR function between oocytes injected with 3 and 4 sub-
units at a 1:1 ratio to that after injection with 3, 4, and
5(V9S) subunits at a 1:1:1 ratio may underestimate the effect
of the gain-of-function mutation. In contrast, co-injection of
the5(V9S) subunit with the concatemeric construct, even at a
3:1 5(V9S):concatemer ratio, produced no change in function
(Fig. 4B). These data demonstrate that at least the great major-
ity of nAChR function arising from injection of the concate-
meric construct mRNAs must be mediated by intact, pentam-
eric nAChR concatemers.
Absolute Efficacy Comparisons between (34)25(Asp-398)
and (34)25(Asn-398) nAChR Concatemers—The studies
above describe partial agonist efficacies normalized to ACh.
However, we wanted to compare absolute agonist efficacies
between constructs containing either the 5(Asp-398) or
5(Asn-398) variants. The use of concatemeric constructs
allows these comparisons to be made without uncertainty
related to the subunit makeup of the functional receptors.
However, efficiency of functional nAChR expression varies
across oocyte preparations and as a function of time post-injec-
tion. To compensate for this form of variation, we used a batch-
to-batch normalization strategy (described in detail under
“Experimental Procedures”).
As shown in Fig. 5A, peak ACh responses mediated by
(34)25(Asn-398) concatemers were significantly lower
than those evoked by stimulation of (34)25(Asp-398) con-
catemers (p  0.001). Thus, although no differences in ACh
potency were observed between 34* nAChR containing the
5(Asp-398) and 5(Asn-398) variants (as measured by their
EC50 values; see Fig. 3A), significant differences were observed
in levels of receptor function (as measured by current magni-
tudes; Fig. 5A). Similar trends were observed when absolute
levels of function were measured in response to maximally effi-
TABLE 1
Pharmacological parameters calculated from concatemeric 34* nAChR and from 345 nAChR expressed from loose subunits
Oocytes injected with RNA encoding either concatenated 34* nAChR or single 3, 4, and 5 subunits in a 1:1:1 ratio were perfused with the nAChR agonists
acetylcholine (106 to 102 M), cytisine (106.25 to 103 M), nicotine (106.5 to 103.5 M), or the nAChR antagonist mecamylamine (107.5 to 104 M). Data are presented as
the mean S.E., with numbers of individual oocytes tested (n) as indicated. * denotes concatemeric constructs.
Acetylcholine Cytisine Nicotine Mecamylamine
Expressed nAChR n Log EC50 nH S.E. n Log EC50 nH S.E. n Log EC50 nH S.E. n Log IC50 nH S.E.
43434* 16 3.9 0.02 1.8 0.11 6 4.8 0.07 1.6 0.4 6 4.2 0.07 1.6 0.4 6 7.4 0.04 0.9 0.05
43433* 11 4.0 0.03 1.4 0.13 6 4.7 0.04 1.2 0.12 6 4.1 0.07 1.8 0.4 6 6.7 0.03 1.1 0.08
43435(Asp-398)* 17 4.0 0.01 1.6 0.06 10 4.8 0.04 1.3 0.15 8 4.2 0.05 1.8 0.4 8 6.2 0.03 1.1 0.08
43435(Asn-398)* 17 4.0 0.02 1.6 0.09 10 4.8 0.03 1.3 0.13 8 4.3 0.06 1.9 0.4 8 6.0 0.03 1.2 0.08
345 (1:1:1) 6 3.8 0.02 1.6 0.10 6 4.7 0.03 1.5 0.2 6 4.4 0.03 2.0 0.2 6 6.4 0.02 1.5 0.09
FIGURE 4. 345 concatemers are expressed as functional pentamers
and are not byproducts of fractional assembly. A, co-injection (1:1:1) of
loose 3 and 4 nAChR subunits with the 5 gain of function subtype (V9S)
enhances receptor function (p  0.01; n  4 oocytes per group). B, overex-
pression of the 5(V9S) subunit has no effect on (34)2(4) concatemer
function (n.s.; n 4 oocytes per group). Panels A and B represent normalized
currents (% of 34 (1:1) or 4(p5), respectively. Normalized currents were
analyzed using one-way ANOVA (see “Experimental Procedures”).
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cacious concentrations of cytisine (Fig. 5B; 300 M) or nicotine
(Fig. 5C; 300 M), although in neither case did these apparent
differences attain statistical significance (p 0.05).
One of the more striking findings was that for each ago-
nist the maximum responses recorded from (34)23 or
(34)24 nAChR were much smaller than those measured
from oocytes expressing either of the (34)25 variant con-
structs (Figs. 5, A–C; see Table 3). Peak currents were indistin-
guishable between (34)23 and (34)24 nAChR for each
agonist. This increased function for 5-containing concatem-
ers is the opposite of the decreased function observed previ-
ously when 5 subunits are co-injected with unlinked 3 and
4 subunits. This observation may indicate that enforcing cor-
rect assembly of5 subunits by use of a concatemeric construct
FIGURE 5.Maximum function comparison between (34)25(Asp-398) and (34)25(Asn-398) nAChR concatemers.Maximal currents (normalized
to (34)25(Asp-398); see “Experimental Procedures”) were compared between 34 and 345-containing concatemers for acetylcholine (A); panels
A1–A4 represent averaged traces for ACh doses (106 to 102.25) for (34)2(4) (n  16), (34)2(3) (n  11), (34)25(Asn-398) (n  17), and
(34)25(Asp-398) (n 17), respectively. Peak ACh responses mediated by (34)25(Asn-398) concatemers were significantly lower than those of evoked
by stimulationof (34)25(Asp-398) concatemers (p 0.001).Maximal currentswere also comparedbetween34 and345 containing concatemers for
cytisine (B);panels B1–B4 represent averaged traces for cytisinedoses (106.25 to 103) for (34)2(4) (n6), (34)2(3) (n6), (34)25(Asn-398) (n10),
and (34)25(Asp-398), (n 8), respectively. However, peak cytisine responses mediated by (34)25(Asn-398) concatemers were not significantly lower
than those of evoked by stimulation of (34)25(Asp-398) concatemers (p 0.05). Additionally, comparisons weremade between concatemers for nicotine
(C); panels C1–C4 represent averaged traces for nicotine doses (106.25 to 103) for (34)2(4) (n 6), (34)2(3) (n 6), (34)25(Asn-398) (n 8), and
(34)25(Asp-398) (n 8), respectively. Again, no differences in peak nicotine responses were observed between (34)25(Asn-398)-containing concate-
mers and (34)25(Asp-398)-containing concatemers (p 0.05).Maximum responses recorded from (34)2(4) and (34)2(3) nAChRweremuch smaller
than those measured from oocytes expressing either of the 5 variant constructs (p 0.001). Comparisons between groups were analyzed using one-way
ANOVA with Tukey’s post hoc comparison (see “Experimental Procedures”).
5(D398N) Effects on34 Nicotinic Receptor Function
JULY 20, 2012•VOLUME 287•NUMBER 30 JOURNAL OF BIOLOGICAL CHEMISTRY 25157
 at ELSEV
IER BV
 on Septem
ber 19, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
reduces inefficiencies of assembly or the formation “dead-end
intermediates” that have previously been observed when
attempting to use self-assembly of individual subunits (30).
Divergent 3:4 RNA Injection Ratios Produce nAChR with
Different Functional Properties—As previously noted, pharma-
cological parameters measured for 345 nAChR were very
similar regardless of whether they were expressed from loose
subunits or from concatemeric constructs. The same was not
true, however, for 34-only subtypes expressed from single
subunits injected at a 1:1 ratio or as concatemers (Figs. 2 and 3).
It has recently been noted that oocytes injected with different
3:4mRNA ratios express34 nAChR populations with dif-
fering pharmacological properties (27, 28). By analogy to more
extensively studied high and low agonist sensitivity 42
nAChR isoforms, it has been speculated that these populations
may correspond to (34)24 and (34)23 stoichiometries
(27, 28) as expressed by the concatemeric constructs produced
in this study.
The pharmacological properties of nAChR arising from co-
injection of 3 and 4 subunits at 1:20 and 20:1 ratios are very
different (Fig. 6). Oocytes injected with 34 in a 20:1 cRNA
injection ratio expressed receptors that were less sensitive to
ACh than those injected with 34 in a 1:20 cRNA injection
ratio (Fig. 6A; EC50 values of 210M (CI, 199–218M) versus 50
M (CI, 43–57 M), respectively; p 0.0001). Cytisine concen-
tration response profiles also differed, yielding lower sensitivity
responses for nAChR in oocytes injected with 20:1 3:4 sub-
unit cRNAs (Fig. 6B, EC50  63 M; CI, 54–74 M) when
compared with those injected with 1:20 subunit ratios (Fig. 6B,
EC50 8.6 M; CI, 6.7 to 11 M; p 0.01). In addition, cytisine
efficacy (normalized to 1mMACh)was 2.3	 greater for oocytes
injected with 3:4 cRNAs at a 20:1 ratio than for oocytes
injected with a 1:20 cRNA ratio (Fig. 6B, 266.5 7.5 to 115.3
2.5%, respectively; p 0.0001). Moreover, nicotine EC50 values
and normalized efficacy values were lower for oocytes injected
with 3:4 subunit cRNAs in a 1:20 ratio than in a 20:1 ratio
(Table 2; 25 M (CI, 20–33 M) to 46 M (CI, 39–55 M)
respectively, p  0.05). Nicotine was more efficacious for
oocytes injected with 3:4 cRNAs at a 20:1 ratio than for
oocytes injected with a 1:20 cRNA ratio (Fig. 6C, 151.9 5.4%
compared with 95.1 8.2% of 1 mM ACh control, respectively;
p  0.01). Finally, oocytes injected with 3:4 cRNA at a 20:1
ratio were more sensitive to antagonism by mecamylamine
than oocytes injected at a 1:20 ratio (Fig. 6D, 0.12M (CI, 0.07–
0.18 M) to 0.89 M (CI, 0.8–1.0 M) respectively, p 0.001).
Overall, the pharmacological properties measured from
oocytes injected with 3:4 cRNAs in a 1:1 or a 1:20 ratio more
closely resembled each other than those recorded from oocytes
injected at a 20:1 ratio (Table 3). The very similar properties of
nAChR arising from 1:1 or 1:20 3:4 mRNA injection ratios
indicate that the same subunit assembly pattern predominates
in both cases. This confirms previous reports that Xenopus
oocytes injected with 1:1 and 1:9 3:4 mRNA ratios express
similar 34 nAChR populations, whereas high 3:4 mRNA
injection ratios result in expression of a distinctly different
34 nAChR isoform (27, 28). However, none of the outcomes
observed from oocytes injected with any ratio of 3:4mRNAs
closely resembled the results obtained from the concatemeric
FIGURE 6.Concentration responseprofiles for34-only nAChRexpressed as loose subunits.Oocytes injectedwith RNA for3 and4 subunits in a 1:20
or 20:1 ratiowere perfusedwith nAChR agonists acetylcholine (106 to 102, n 4) (A), cytisine (106.25 to 103; n 4) (B), nicotine (106.5 to 103.5; n 4) (C),
or the nAChR antagonist mecamylamine (107.5 to 104; n 4) (D). Data points represent averages (S.E.). Differences in drug potency and efficacy between
groups were analyzed using one-way ANOVA with Tukey’s post hoc comparison (see “Experimental Procedures”).
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constructs or after co-injection of single 3, 4, and 5 sub-
units (Table 1).We conclude that the presence of an5 subunit
or the use of concatemeric constructs results in the assembly of
functional nAChR with similar pharmacological properties.
These properties are likely the hallmark of assembly into a for-
mat containing two (3/4) subunit interfaces, with the addi-
tion of a fifth subunit in a non-ligand binding role. This conclu-
sion is supported by a very recent study showing similar
pharmacological profiles of (34)2X nAChR assembled from
3-4 dimeric concatemers with the addition of single 3, 4,
or 5 subunits (37). Without the constraints imposed by the
concatemeric linkers or by the need to integrate a non-ligand
binding 5 subunit, it seems possible that 3 and 4 subunits
are free to assemble into at least two other formats. The relative
proportions of the two formats expressed in theXenopusoocyte
system can be altered by biasing the 3:4 nAChR subunit
mRNA injection ratio.
DISCUSSION
The pentameric concatemer approach allows accurate and
consistent reproduction of complex nAChR subtypes, with
complete control over subunit ratios and associations (5, 31, 38,
39). It also allows for mutagenesis of a single subunit within an
entire nAChR complex evenwheremultiple copies of the target
subunit may be present. These unique advantages were central
to the work presented in this study. Using concatemeric
345 nAChR, we show that 5 subunit risk variant (Asn-
398) incorporation reduces ACh-evoked function when com-
pared with inclusion of the 5 common variant (Asp-398).
Coexpression of unlinked 3, 4, and 5 subunits enforces
assembly of an apparently uniform nAChR population with
very similar pharmacological properties to those of concate-
meric 34* nAChR. In addition, either variant of the 5 sub-
unit is capable of reducing the overall amount of 34* nAChR
function after coinjection with non-concatenated 3 and 4
subunits. Further observations suggested that removing the
constraints imposed by either concatemerization or by co-ex-
pression with unlinked5 subunits allows loose3 and4 sub-
units to assemble into at least two further subtypes. These
34-only subtypes have substantially different pharmacolog-
ical profiles from each other, from unlinked subunit 345
nAChR, and from any of the concatenated 34 or 345
nAChR.
Critically, the pharmacological properties of345 nAChR
expressed using pentameric concatemers were similar to those
of the same subtype expressed from unlinked subunits. This
finding indicates that the addition of the concatemeric linkers
did not noticeably alter nAChR function. It also reinforces fur-
ther that pentameric concatemers faithfully replicate the ligand
sensitivity of the equivalent subunit arrangement when formed
from loose subunits. It has been suggested that 5 subunits
competewith4 subunits (20, 29), reducing expression of func-
tional 345 nAChR, possibly by encouraging the formation
of dead-end intermediates that become trapped inside the cell
(30). Our observations support this concept. Coinjection of
non-concatenated 5 subunit mRNA approximately halved
34* functional expression in Xenopus oocytes compared
with injection of loose 3 and 4 subunits only (1:1:1 or 1:1
ratios were used; see the legend to Fig. 2). In contrast, if the 5
subunit is forced by concatemerization to assemble only as part
of a pentameric nAChR complex, its incorporation substan-
tially increases functional expression (Fig. 5). Together, these
observations suggest that a reduction in function is not caused
by the incorporation of5 subunits per se. Instead, the presence
of loose 5 subunits likely adversely affects the efficiency of
unlinked 3 and 4 nAChR subunit assembly into functional
nAChR.
In contrast, 34-only nAChR expressed from pentameric
concatemers had different pharmacological properties from
those expressed from loose subunits (Table 1, top two rows, and
Table 2). This discrepancy could be explained in several ways.
One possibility is that covalent linkers may alter the properties
of concatemeric nAChR by constraining structural transitions
that are essential for normal function. This concern ismitigated
by previous publications (5, 31, 38, 39) indicating that well
designed pentameric nAChR concatemers can accurately
reproduce the properties of multiple native nAChR subtypes
TABLE 2
Agonist efficacies compared between concatemeric (34)2X nAChR, where X is either 4, 3, 5(Asn-398) or 5 (Asp-398)
Maximal currents (normalized to (34)25(Asp-398); see “Experimental Procedures”) were compared between 34* nAChR concatemers for acetylcholine (106 to
102.25 M), cytisine (106.25 to 103 M), and nicotine (106.25 to 103 M). Data are presented as the mean S.E., with numbers of individual oocytes tested (n) as indicated.
Compound n (34)24(% of Asp-398) n (34)23(% of Asp-398) n (34)25(Asn-398)(% of Asp-398) n (34)25(Asp-398) concatemer
Acetylcholine 16 11 1.0 11 9 1.0 17 63 7.0 17 100 5.0
Cytisine 6 5 1.0 6 6 1.0 10 80 11.0 10 100 14.0
Nicotine 6 11 4.0 6 9 3.0 8 85 9.0 8 100 4.0
TABLE 3
Pharmacological parameters calculated from 34-only nAChR expressed from different injected subunit ratios
Oocytes injected with RNA for 3 and 4 subunits in a 1:1, 1:20, or 20:1molar ratio were perfused with the nAChR agonists acetylcholine (106 to 102 M), cytisine (106.25
to 103 M), nicotine (106.5 to 103.5 M), or the nAChR antagonist mecamylamine (107.5 to 104 M). Data are presented as the mean S.E., with numbers of individual
oocytes tested (n) as indicated.
Acetylcholine Cytisine Nicotine Mecamylamine
Expressed nAChR n Log EC50 nH S.E. n Log EC50 nH S.E. n Log EC50 nH S.E. n Log IC50 nH S.E.
34 (1:1) 6 4.2 0.02 1.3 0.07 6 4.7 0.03 1.3 0.13 6 4.7 0.04 1.3 0.14 6 5.3 0.04 1.4 0.18
34 (1:20) 4 4.3 0.02 0.96 0.07 4 5.1 0.05 1.1 0.13 4 4.6 0.05 1.3 0.17 4 6.0 0.03 1.2 0.1
34 (20:1) 4 3.7 0.01 1.8 0.06 4 4.2 0.03 1.5 0.14 4 4.3 0.04 2.2 0.3 4 6.9 0.1 1.2 0.14
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(which assemble from unlinked subunits). In addition, the link-
ers in each of the pentameric concatemers used in this study are
of the same length and composition; it is unlikely that only the
non-5* concatemers used in this studywould suffer from link-
er-induced functional alterations. Furthermore, if the non-5*
concatemers were uniquely affected by the presence of the link-
ers, it would be expected that this would strongly alter agonist
potencies and relative efficacies when compared with those of
the 5* concatemers. This is not the case; the pharmacological
parameters measured from all four of the concatemers tested
here are strikingly similar. A second possibility is that the cova-
lent linkers within the concatemers might break down. This
would release sub-pentameric products that could assemble to
form unintended, but functional, byproducts (4, 34, 35). The
presence of suchdegradation productswas checked for by coin-
jection with an 5(V9S) mutant subunit. Assembly of this
mutant subunit with either single 3 and 4 subunits or sub-
pentameric concatemers would result in a substantial gain of
function (34, 36). No change in function was noted when
5(V9S) was co-injected with a concatemeric construct. This
confirms that all, or nearly all, of the function in oocytes
injectedwith pentameric nAChRmRNAconstructs arises from
fully-pentameric concatemeric nAChR. Finally, and most
likely, the precise subunit associations imposed by concate-
meric constructs may, or may not, correspond to those favored
during association of loose subunits. Our data suggest that the
345 concatemers accurately reproduce the conformation
adopted when the relevant individual subunits assemble freely.
However, the same is not true for the 34-only constructs
when compared with nAChR assembled from loose 3 and 4
subunits. This would indicate that one role of the 5 subunit is
to impose a particular subunit composition on 34* nAChR
expressed from loose subunits. If 5 is a true “accessory” sub-
unit (i.e. does not interact directly with ligands), this may be
unavoidable; a (34)25 conformation is the only one in
which two pairs of 34 subunits would be available to pro-
vide agonist binding pockets and thus to assemble a functional
345 nAChR.
The preceding observations raise the question of which
nAChR subtype(s) is expressed after coinjection of only 3 and
4 subunits. This study confirms prior reports that at least two
34 nAChRpopulationsmay be formed and that their relative
expression levels depend on the molar injection ratio of the
subunitmRNAs (1:20 versus 20:1). The pharmacology observed
in this studymatches that reported in other recent publications
(27, 28) that used less-extreme injection ratios (1:9 versus 9:1 or
1:10 versus 10:1). The lack of further changes in observed phar-
macology after adoption of more extreme subunit ratios indi-
cates that, as for 4 and 2 subunits (2, 40, 41), relatively pure
populations of two different 34 subunit assemblies are pro-
duced at the injection ratios used in this study. The same stud-
ies proposed again by analogy to the well-studied 42 nAChR
that the different nAChR isoforms might correspond to
(34)24 and (34)23 nAChR (27).
Accordingly we constructed (34)24 and (34)23 con-
catemers using the same subunit arrangements as used success-
fully to encode high and low agonist sensitivity pentameric
42 nAChR concatemers (5). We initially anticipated that
these concatemerswould have similar pharmacological profiles
to 34-only nAChR formed after injection of loose 3 and 4
subunits at 1:20 and 20:1 ratios, respectively. However, the
pharmacology observed after injection of loose 3 and 4 sub-
units at either 1:20 or 20:1 ratios (Fig. 6, Table 2) was strikingly
different from the concatemeric “(34)2X-type” measure-
ments. The precise arrangements adopted by loose 3 and 4
subunits injected at different ratios remain unknown. It cer-
tainly seems probable that 1:20 and 20:1 3:4 injection ratios
may give rise to nAChR with different stoichiometries (27, 28).
In addition, as demonstrated for GABAA receptors, the precise
order of subunit incorporation (even for identical subunit sto-
ichiometries) can affect receptor function (42). The emerging
awareness that agonist binding to non-canonical nAChR inter-
faces can strongly affect function underlines this point (5, 41,
43). Determining whether different 3:4 subunit mRNA
injection ratios produce nAChRwith different stoichiometries,
different arrangements of the same subunit stoichiometries, or
both will require a great deal more investigation. The concate-
meric pentamer approach is uniquely well suited to addressing
this question.
Unlike agonist EC50 values, IC50 values for mecamylamine
inhibition were greatly affected by the identity of the fifth
subunit in each pentameric concatemer. This suggests that
mecamylamine (a non-competitive antagonist) interacts with
the resulting nAChR in a position where it can be influenced by
the presence of alternate subunits in the fifth, non-agonist-
binding position. This sensitivity to34* nAChR composition
was also evident when comparing mecamylamine IC50 values
between 34 and 345 nAChR expressed from loose
subunits (Table 1). These observations indicate that non-
competitive ligands may provide the best opportunities to
pharmacologically distinguish between different subunit
arrangements of 34* isoforms. Importantly, this category
could also include positive allosteric modulators and/or allos-
teric agonists in addition to non-competitive antagonists.
Given the association of 5 subunit variants with a variety of
substance abuse behaviors (see introduction), selective manip-
ulation of 345 nAChR activity could have valuable thera-
peutic implications.
Functional effects of the 5(D398N) mutation are hard to
distinguish without using a fully pentameric concatemer ap-
proach. The previously described effects of 5 subunits on
the efficiency of 34* nAChR expression and possibly also
on subunit associations/assembly could outweigh and
obscure the effects of the 5(D398N) mutation. This could
explain previous studies’ conclusions that the effects of
5(Asp-389) incorporation were the same as those of
5(Asn-389) (18, 25, 37). However, using a pentameric
concatemer approach, we were able to compare the func-
tion of uniform populations of (34)25(Asp-389) versus
(34)25(Asn-389) nAChR. The maximum ACh-induced
function produced by (34)25(Asp-389) nAChR was signif-
icantly greater than that measured for (34)25(Asn389)
nAChR (Fig. 5). Increased function for 5(Asp-398)* versus
5(Asn-398)* nAChR with little difference in pharmacological
profile matches previous observations regarding 5 variant
incorporation into 42* nAChR (11, 18).
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It appears that, as previously proposed (20), 5 subunit
expression may act to modulate the amount of 34* nAChR
function in the habenulopeduncular tract and in other tissues
that express345nAChR.This study indicates that the pres-
ence of the 5(Asp-398) or 5(Asn-398) variant will impose an
additional layer of functional modulation. As noted previously
(18), the concentrations of nicotine present in smokers are too
low to significantly activate or desensitize 345 nAChR.
However, the activity induced by synaptic or perisynaptic ACh
release onto 34* nAChR could be strongly affected by the
integration of 5(Asp-398) or 5(Asn-398) subunits. This in
turn could result in compensatory changes either at the neu-
rotransmitter/receptor level or at the circuit activity level,
whichmay explain someof the phenotypic variations attributed
to the 5(D398N) mutation. Given the established role of the
habenulopeduncular pathway 345 nAChR function in nic-
otine dependence and aversive behavior (20, 44, 45), it seems
likely that selectivemanipulation of345 functionmediated
by this subtype could represent a valuable smoking cessation
strategy. Our current findings indicate that non-competitive/
allosteric compounds may be the most promising category of
potential therapeutic agents for such an approach.
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